SCHEDULE: Barclays PLC Discloses 4.23% Stake in Myriad Genetics
Beneficial Ownership Report (Schedule 13G Amendment)
Barclays PLC has reported a 4.23% beneficial ownership stake in Myriad Genetics Inc. common stock as of September 30, 2025.
Summary
- Barclays PLC beneficially owns 3,939,238 shares of Myriad Genetics Inc. common stock.
- This ownership represents 4.23% of the total class of securities.
- Barclays PLC holds sole voting power and sole dispositive power over all 3,939,238 shares.
- The filing was made under Rule 13d-1(b), indicating the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control of Myriad Genetics Inc.
- Subsidiaries identified as acquiring the security include Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd.
Sentiment
Score: 6
Explanation: The filing itself is a neutral regulatory disclosure of beneficial ownership. However, the presence of a significant institutional investor like Barclays PLC holding a stake in Myriad Genetics Inc. is generally viewed as a positive signal of institutional confidence in the company.
Positives
- A significant institutional investor like Barclays PLC holding a 4.23% stake can signal confidence in Myriad Genetics Inc.'s long-term prospects.
- The filing under Rule 13d-1(b) indicates the investment is for ordinary course business, not an activist play, which can provide stability.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding Myriad Genetics Inc.'s operational or financial performance, focusing solely on beneficial ownership disclosure.
Industry Context
Schedule 13G filings are routine disclosures by institutional investors, such as banks and investment funds, when they acquire a significant percentage of a company's voting stock. This filing indicates Barclays PLC's updated passive investment in Myriad Genetics Inc., a company typically involved in genetic testing and precision medicine. Such institutional holdings are common and reflect investment portfolio management.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Barclays PLC may instill confidence among existing shareholders and potentially attract new investors, indicating institutional interest in Myriad Genetics Inc.
- Management: Awareness of a large institutional holder may influence management's strategic decisions, though Barclays PLC has certified it is not seeking to influence control.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event requiring the filing of this statement, indicating the beneficial ownership position. |
| 11/12/2025 | Date the Schedule 13G Amendment No. 1 was signed by Barclays PLC. |
Keywords
Barclays PLC, Myriad Genetics Inc, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, SEC Filing, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.